Home/Filings/4/0001415889-25-003295
4//SEC Filing

Posner Christopher 4

Accession 0001415889-25-003295

CIK 0001346830other

Filed

Feb 5, 7:00 PM ET

Accepted

Feb 6, 7:15 PM ET

Size

5.9 KB

Accession

0001415889-25-003295

Insider Transaction Report

Form 4
Period: 2025-02-04
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
  • Sale

    Common Stock

    2025-02-04$4.72/sh372$1,75613,692 total
Footnotes (3)
  • [F1]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
  • [F2]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The total number of securities reported as beneficially owned following the reported transaction reflects the 1-for-12 reverse stock split that was effected by the Issuer on December 30, 2024.

Issuer

Cara Therapeutics, Inc.

CIK 0001346830

Entity typeother

Related Parties

1
  • filerCIK 0001748265

Filing Metadata

Form type
4
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 7:15 PM ET
Size
5.9 KB